References

  1. Global tuberculosis report 2023. Geneva: World Health Organization; 2023 (https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023, accessed 8 November 2023).
  2. Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/361989, accessed 31 August 2023).
  3. The end TB strategy. Geneva: World Health Organization; 2015 (https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19, accessed 31 August 2023).
  4. Political Declaration on the High-Level Meeting on the Fight Against Tuberculosis “Advancing science, finance and innovation, and their benefits, to urgently end the global tuberculosis epidemic, in particular by ensuring equitable access to prevention, testing, treatment and care”. New York: United Nations; 2023 (https://www.un.org/pga/77/wp-content/uploads/sites/105/2023/09/TB-Final-Text.pdf, accessed 4 October 2023).
  5. Resolution A/RES/75/284. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Resolution adopted by the General Assembly on 8 June 2021. New York: United Nations; 2021 (https://digitallibrary.un.org/record/3928975?ln=en, accessed 26 September 2023).
  6. Political Declaration of the High-level Meeting on Universal Health Coverage “Universal Health coverage: expanding our ambition for health and well-being in a post-COVID world”. New York: United Nations; 2023 (https://www.un.org/pga/77/wp-content/uploads/sites/105/2023/09/UHC-Final-Text.pdf, accessed 21 November 2023)
  7. WHO operational handbook on tuberculosis. Module 6: tuberculosis and comorbidities. Geneva: World Health Organization; 2023. 
  8. Multisectoral accountability framework to accelerate progress to end tuberculosis by 2030. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 (https://apps.who.int/iris/handle/10665/331934, accessed 21 November 2023)
  9. Interim policy on collaborative TB/HIV activities. Geneva: World Health Organization; 2004 (https://apps.who.int/iris/handle/10665/78705, accessed 31 August 2023).
  10. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/44789, accessed 31 August 2023).
  11. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/352522, accessed 26 September 2023).
  12. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340255, accessed 31 August 2023).
  13. WHO consolidated guidelines on tuberculosis. Module 1: prevention – infection prevention and control. World Health Organiztion; 2022 (https://apps.who.int/iris/handle/10665/362508, accessed 26 September 2023).
  14. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342331, accessed 31 August 2023).
  15. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – tests for tuberculosis infection. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/362936, accessed 31 August 2023).
  16. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/365308, accessed 31 August 2023).
  17. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/353829, accessed 31 August 2023).
  18. WHO consolidated guidelines on tuberculosis. Module 4: treatment – tuberculosis care and support. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/353399, accessed 31 August 2023).
  19. Guidance for national tuberculosis programmes on the management of tuberculosis in children – 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/112360, accessed 26 September 2023).
  20. Diagnosing and managing disseminated histoplasmosis among people living with HIV. Washington, D.C.: Pan American Health Organization, World Health Organization; 2020 (https://iris.paho.org/handle/10665.2/52304, accessed 26 September 2023).
  21. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 31 August 2023).
  22. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331170, accessed 31 August 2023).
  23. Consolidated guidelines on HIV testing services, 2019. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/336323, accessed 26 September 2023).
  24. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. Geneva; 2017 (9789241550062; https://apps.who.int/iris/handle/10665/255884, accessed 26 September 2023).
  25. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring: March 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 26 September 2023).
  26. WHO standard: universal access to rapid tuberculosis diagnostics. Geneva: World Health Organization; 2023 (https://apps.who.int/iris/handle/10665/366854, accessed 26 September 2023).
  27. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/360348, accessed 26 September 2023).
  28. Global AIDS strategy 2021-2026. Geneva: The Joint United Nations Programme on HIV/ AIDS (UNAIDS); 2021 (https://www.unaids.org/sites/default/files/media_asset/global-AIDSstrategy-2021-2026_en.pdf, accessed 26 September 2023).
  29. Political declaration on the United Nations high-level meeting on the fight against tuberculosis “Advancing science, finance and innovation, and their benefits, to urgently end the global tuberculosis epidemic, in particular by ensuring equitable access to prevention, testing, treatment and care”. New York: United Nations General Assembly; 2023 (https://www.un.org/pga/77/wp-content/uploads/sites/105/2023/09/TB-Final-Text.pdf, accessed 9 October 2023).
  30. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/360601, accessed 26 September 2023).
  31. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/357088, accessed 26 September 2023).
  32. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and metaanalysis. AIDS. 2015;29:1987–2002. doi: 10.1097/QAD.0000000000000802. 
  33. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44472, accessed 26 September 2023).
  34. Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC infectious diseases. 2009;9:53-. doi: 10.1186/1471-2334-9-53.
  35. Whitelaw A, Peter J, Sohn H, Viljoen D, Theron G, Badri M et al. Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients. Eur Respir J. 2011;38:1393-7. doi: 10.1183/09031936.00023211.
  36. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44586, accessed 26 September 2023).
  37. Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/330395, accessed 26 September 2023).
  38. Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C et al. Evaluation of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. Journal of clinical microbiology. 2013;51:2311-6. doi: 10.1128/JCM.00330-13.
  39. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://iris.who.int/handle/10665/342369, accessed 26 September 2023).
  40. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50:1288- 99. doi: 10.1086/651686.
  41. Caceres DH, Valdes A. Histoplasmosis and tuberculosis co-occurrence in people with advanced HIV. J Fungi (Basel). 2019;5. doi: 10.3390/jof5030073.
  42. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994;18:266-7. doi: 10.1093/ CLINIDS/18.2.266.
  43. Agudelo CA, Restrepo CA, Molina DA, Tobón AM, Kauffman CA, Murillo C et al. Tuberculosis and histoplasmosis co-infection in AIDS patients. Am J Trop Med Hyg. 2012;87:1094-8. doi: 10.4269/ajtmh.2012.12-0292.
  44. Integration of HIV and TB services: a: does ART provided at the TB clinic result in better outcomes than referring people with TB and HIV for ART in specialized HIV clinics? b: does TB diagnosis and/or TB treatment at specialized HIV clinics result in better outcomes than referring people living with HIV to TB clinics for TB diagnosis and/or TB treatment? Geneva: World Health Organization & University of California, San Francisco; 2013 (https://iris.who.int/handle/10665/94591, accessed 11 October 2023).
  45. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384:682-90. doi: 10.1016/S0140-6736(14)60162-8.
  46.  Schechter M. Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials. J Int AIDS Soc. 2018;21. doi: 10.1002/jia2.25077.
  47. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: longterm follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5:e1080-e9. doi: 10.1016/S2214-109X(17)30372-8.
  48. Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond). 2017;49:161-9. doi: 10.1080/23744235.2016.1262059.
  49. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;2010:CD000171. doi: 10.1002/14651858. CD000171.pub3. 
  50. Chaisson LH, Saraceni V, Cohn S, Seabrook D, Cavalcante SC, Chaisson RE et al. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS. 2020;34:139-47. doi: 10.1097/QAD.0000000000002398.
  51. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808-22. doi: 10.1056/NEJMoa1507198.
  52. Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. Ann Intern Med. 2021;174:1367-76. doi: 10.7326/M20-7577.
  53. Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update. Geneva: World Health Organization; 2015 (https://iris.who.int/handle/10665/174052, accessed 27 September 2023).
  54. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services. J Infect Dis. 2012;205 Suppl 2:S216-27. doi: 10.1093/infdis/jis009.
  55. Isoniazid tablets, USP. Maryland: United States Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 11 October 2023).
  56. RIFADIN® (rifampin capsules USP) and RIFADIN® IV (rifampin for injection USP). Maryland: United States Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 11 October 2023).
  57.  Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391. doi: 10.1371/journal.pmed.1000391.
  58. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended four symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5:e515-e23. doi: 10.1016/S2352- 3018(18)30137-1.
  59. Nguyen DT, Bang ND, Hung NQ, Beasley RP, Hwang LY, Graviss EA. Yield of chest radiograph in tuberculosis screening for HIV-infected persons at a district-level HIV clinic. Int J Tuberc Lung Dis. 2016;20:211-7. doi: 10.5588/ijtld.15.0705.
  60. Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS. 2014;28:1463-72. doi: 10.1097/QAD.0000000000000278.
  61. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/252424, accessed 27 September 2023).
  62. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/handle/10665/44759, accessed 27 September 2023).
  63. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018 (https://iris.who.int/handle/10665/260233, accessed 27 September 2023).
  64. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:45-55. doi: 10.1016/S1473-3099(11)70210-9.
  65. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M et al. The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One. 2011;6:e17984. doi: 10.1371/journal.pone.0017984.
  66. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016;193:1421-8. doi: 10.1164/rccm.201508- 1595OC.
  67. McCarthy KM, Scott LE, Gous N, Tellie M, Venter WDF, Stevens WS et al. High incidence of latent tuberculous infection among South African health workers: an urgent call for action. Int J Tuberc Lung Dis. 2015;19:647-53. doi: 10.5588/ijtld.14.0759. 
  68. Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One. 2017;12:e0169539. doi: 10.1371/journal.pone.0169539.
  69.  Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000;1999:CD001363. doi: 10.1002/14651858. CD001363.
  70. Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIVinfected children. Cochrane Database Syst Rev. 2017;8:CD006418. doi: 10.1002/14651858. CD006418.pub3.
  71. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167:248-55. doi: 10.7326/M17-0609.
  72.  Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-50.
  73. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419-28. doi: 10.7326/M14-1019.
  74. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/136471, accessed 27 September 2023).
  75. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J et al. Safety and side effects of rifampin versus isoniazid in cildren. N Engl J Med. 2018;379:454-63. doi: 10.1056/ NEJMoa1714284.
  76. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445-9. doi: 10.1164/rccm.200404-478OC.
  77. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689-97. doi: 10.7326/0003-4819-149-10- 200811180-00003.
  78. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001- 11. doi: 10.1056/NEJMoa1806808. 
  79. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365:11-20. doi: 10.1056/ NEJMoa1005136.
  80. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66. doi: 10.1056/NEJMoa1104875.
  81. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIVcoinfected persons. AIDS. 2016;30:1607-15. doi: 10.1097/QAD.0000000000001098.
  82. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247-55. doi: 10.1001/jamapediatrics.2014.3158.
  83. Den Boon S, Matteelli A, Ford N, Getahun H. Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. AIDS. 2016;30:797-801. doi: 10.1097/ QAD.0000000000000985.
  84. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61:1322-7. doi: 10.1093/CID/CIV464.
  85. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69:1079-85. doi: 10.1093/JAC/DKT483.
  86. Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P et al. Cytokine-mediated systemic adverse drug reactions in a drug-drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine. Clin Infect Dis. 2018;67:193-201. doi: 10.1093/cid/ciy082.
  87. Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7:e401-e9. doi: 10.1016/S2352- 3018(20)30032-1.
  88. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Annex 2. GRADE summary of evidence tables (for new recommendations in 2018 & 2019 guidelines updates). Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/330865, accessed 27 September 2023).
  89. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/251730, accessed 27 September 2023).
  90. Joshi R, Reingold AL, Menzies D, Pai M. tuberculosis among health-care workers in low- and middle-income countries: a systematic review. PLoS Med. 2006;3:e494. doi: 10.1371/journal. pmed.0030494.
  91. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388:1228-48. doi: 10.1016/ S0140-6736(16)30856-X.
  92. Dhavan P, Dias HM, Creswell J, Weil D. An overview of tuberculosis and migration. Int J Tuberc Lung Dis. 2017;21:610-23. doi: 10.5588/ijtld.16.0917.
  93. WHO operational handbook on tuberculosis: Module 1: prevention – infection prevention and control. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/372738, accessed 27 September 2023).
  94. Srikantiah P, Lin R, Walusimbi M, Okwera A, Luzze H, Whalen CC et al. Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. Int J Tuberc Lung Dis. 2007;11:168-74.
  95. Odhiambo J, Kizito W, Njoroge A, Wambua N, Nganga L, Mburu M et al. Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya. Int J Tuberc Lung Dis. 2008;12:63-8.
  96. Nliwasa M, MacPherson P, Gupta-Wright A, Mwapasa M, Horton K, Odland J et al. High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses. J Int AIDS Soc. 2018;21. doi: 10.1002/JIA2.25162.
  97. Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs: consolidated guidelines. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/204484, accessed 27 September 2023).
  98. Waldrop G, Doherty M, Vitoria M, Ford N. Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy. Trop Med Int Health. 2016;21:1124-30. doi: 10.1111/tmi.12746.
  99. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-29. doi: 10.1016/s0140-6736(02)09411-4.
  100. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O’Shaughnessy MV et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-77. doi: 10.1001/jama.286.20.2568.
  101. Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis. 2012;55:1707-18. doi: 10.1093/cid/cis797.
  102. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004;5:93-8. doi: 10.1111/j.1468- 1293.2004.00193.x. 
  103. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173-82. doi: 10.1016/S0140-6736(15)60164-7.
  104. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377:233-45. doi: 10.1056/NEJMoa1615822.
  105. Merle C, Floyd S, Ndiaye A, Galperine T, Furco A, de Jong BC et al. High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: the RAFA trial results. In: Proceedings. 21st International AIDS Conference; Durban, South Africa, July 18-22, 2016.
  106. Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A et al. Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts < 200 cells/μL: TB-HAART study, a randomized cinical trial. PloS one. 2015;10:e0122587-e. doi: 10.1371/journal.pone.0122587.
  107. Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009;25:1277-85. doi: 10.1089/ aid.2009.0100.
  108. Blanc F-X, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471- 81. doi: 10.1056/NEJMOA1013911. 
  109. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70:549- 56. doi: 10.1093/cid/ciz256.
  110. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573. doi: 10.1016/j.eclinm.2020.100573.
  111. Jamal L, Guibu I, Tancredi M, Ramalho M, Vasconcelos G, Cota I. Reliability and usefulness of TB/ HIV co-infection data proceeding from developing countries. In: Proceedings. XV International AIDS Conference, Bangkok, Thailand; 2004.
  112. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC infectious diseases. 2009;9:42-. doi: 10.1186/1471-2334-9-42.
  113. Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182-9.
  114. Palmero D, Ritacco V, Ambroggi M, Poggi S, Güemes Gurtubay J, Alberti F et al. Multidrugresistant tuberculosis in AIDS patients at the beginning of the millennium. Medicina. 2006;66:399-404.
  115. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007;30:623-6. doi: 10.1183/09031936.00077307.
  116. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J. 2010;36:584-93. doi: 10.1183/09031936.00003710.
  117. El Sahly HM, Teeter LD, Pawlak RR, Musser JM, Graviss EA. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J Infect. 2006;53:5-11. doi: 10.1016/J.JINF.2005.10.002. 
  118. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14:1700-6. doi: 10.3201/EID1411.080729.
  119. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-807. doi: 10.1016/S0140-6736(10)60492-8.
  120. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura LM, Schecter G et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis. 2005;40:968-75. doi: 10.1086/428582.
  121. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ. 2008;337:220-3. doi: 10.1136/BMJ.A257.
  122. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1- infected patients with tuberculosis in Abidjan, Côte d’Ivoire: a randomised controlled trial. Lancet. 1999;353:1469-75. doi: 10.1016/S0140-6736(99)03465-0.
  123. Zachariah R, Spielmann MP, Harries AD, Salaniponi FL. Voluntary counselling, HIV testing and sexual behaviour among patients with tuberculosis in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7.
  124. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis. 2004;8:938-44.
  125. Mwaungulu FBD, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ. 2004;82:354-63.
  126. Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, Getahun H et al. Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health. 2013;18:199-211. doi: 10.1111/TMI.12029.
  127. The role of HIV viral suppression in improving individual health and reducing transmission: policy brief. Geneva: World Health Organization; 2023 (https://iris.who.int/handle/10665/360860, accessed 28 September 2023).
  128.  Gupta A, Bhosale R, Kinikar A, Gupte N, Bharadwaj R, Kagal A et al. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011;203:358-63. doi: 10.1093/infdis/jiq064.
  129. Safe management of wastes from health-care activities: a summary. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/259491, accessed 28 September 2023).
  130. Gunneberg C, Reid A, Williams BG, Floyd K, Nunn P. Global monitoring of collaborative TB-HIV activities. Int J Tuberc Lung Dis. 2008;12:S2-S7.
  131. Martinot A, Van Rie A, Mulangu S, Mbulula M, Jarrett N, Behets F et al. Baseline assessment of collaborative tuberculosis/HIV activities in Kinshasa, the Democratic Republic of Congo. Trop Doct. 2008;38:137-41. doi: 10.1258/TD.2007.070063.
  132. Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331697, accessed 28 September 2023).
  133. A guide to monitoring and evaluation for collaborative TB/HIV activities – 2015 revision. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/150627, accessed 28 September 2023).
  134. Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings. Geneva: World Health Organization; 2010 (https://apps.who.int/iris/handle/10665/44431, accessed 28 September 2023).
Convert to pdf
Off

Book navigation